DOP junks Geltec plea against NPPA decision on retail price of Ibuprofen Soft Gelatin Capsules
New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Geltec Private Limited against National Pharmaceutical Pricing Authority (NPPA) for price fixation of its formulations "Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules".
However, the NPPA did not fix the retail prices of the said formulations and directed the company to follow the ceiling price of Ibuprofen 400mg and 200mg hard gelatin capsules notified in 2018.
Having been aggrieved by the response of the NPPA, Geltec submitted the review application to the department for separate retail prices for its formulations. As per the para 31 of the DPCO, any person aggrieved by any notification issued or order made under paragraph 4, 5 and 6 of the DPCO, may apply to the Government for a review of the notification or order.
In the instant case, the petitioner, GELTEC filed a review against the NPPA which was simply a reply to the company against its Form I application. Noting this, DOP rejected the company's plea
"Filing of a review application against a letter is not as per the provisions laid down in the DPCO. Hence, the review application is liable to be rejected," reads the order.
Subsequently, DOP rejected the plea filed by Geltec against NPPA.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at email@example.com Contact no. 011-43720751 To know about our editorial team click here